Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: iStock
Fatty liver disease, which affects nearly 30% of adults worldwide, may comprise five biologically distinct subtypes, according to new research.
Researchers from the Mayo Clinic and Virginia Tech in the US found that each subtype may carry different risks of liver failure, cancer, heart disease and other serious complications.
The study, published in Nature Communications, suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) can develop through different biological pathways. Some are closely linked to obesity and diabetes, while others appear to be driven by inherited genetic factors.
The findings suggest that genetic forms of the disease may progress to advanced liver damage even in people without typical metabolic risk factors.
Also read: NAFLD to MASLD: Experts Explain Why This Common Yet Dangerous Liver Condition Got Renamed
MASLD, previously known as nonalcoholic fatty liver disease, develops when excess fat accumulates in the liver. Many people experience no noticeable symptoms, allowing the condition to go undetected for years.
Although the disease does not always cause serious complications, it can progress to inflammation, scarring and permanent liver damage. In advanced cases, it may lead to cirrhosis, in which extensive scarring impairs liver function.
MASLD is a major contributor to cirrhosis, liver cancer and liver transplantation worldwide. Understanding why some patients develop severe complications while others do not is therefore an important research priority.
To investigate the differences, the researchers analyzed genetic sequencing results alongside detailed medical records from more than 4,600 patients with MASLD.
The data included liver enzyme measurements, body mass index, blood lipid levels and other indicators of metabolic health. The researchers also examined coexisting conditions, including diabetes, depression and sleep apnea.
Using computational models, they identified five groups of patients who shared distinct biological characteristics. The findings suggest that people with the same MASLD diagnosis may have different underlying disease processes and risks of complications.
“When clinical and genomic data are analyzed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden,” said Shulan Tian, Ph.D., co-senior author and a bioinformatician at Mayo Clinic. “Once you separate these subtypes, you can start to match treatments to the biology that's actually driving the disease.”
Read More: Lancet Study Shows Metabolic Liver Disease To Rise Over 38% By 2050: What’s Behind The Surge
The findings also suggest that the differences between MASLD subtypes extend beyond the liver.
Researchers identified associations between specific subtypes and conditions such as depression, sleep apnea and migraine. These links suggest that the biological processes underlying some forms of fatty liver disease may also be associated with health problems affecting other parts of the body.
However, the findings do not establish that MASLD directly causes these conditions.
Identifying distinct subtypes could eventually help doctors recognize high-risk patients earlier, improve screening and develop more personalized treatment strategies.
Eric Klee, a research and innovation leader at Mayo Clinic, said the approach could help researchers better understand disease progression and identify opportunities to intervene before severe damage occurs.
The team plans to evaluate the findings in larger and more diverse patient populations and investigate whether the subtypes respond differently to treatments, including GLP-1 receptor agonists.
If further studies validate the results, the research could help move MASLD care toward earlier intervention and treatments tailored to the biological processes driving each patient's disease.
Credit: AP Photos
Even as Republicans struggle to win over female voters two weeks before the midterm elections, US President Donald Trump has signed an executive order backed by First Lady Melania Trump to advance the health of women in America.
The initiative will establish a new Division of Women’s Health within the National Institutes of Health (NIH) and a Women’s Health Task Force within the White House.
The executive order aims to advance women’s health by ensuring that medical research, diagnosis, prevention and treatment reflect the highest-quality scientific evidence, to improve health outcomes at every stage of life.
“Our mission must serve women at every stage of life, from young girls just starting out to mothers dealing with a complex range of responsibilities, to mature women who deserve to have vitality, dignity and independence,” the first lady said.
Trump called the announcement “a big deal” and credited himself with introducing a new initiative. “When I heard about it, I said, ‘Are you sure they don’t have that?’” the president said. “Who the hell wouldn’t have a women’s health division?”
The US has had a dedicated office for women’s health research since 1990, when the Office of Research on Women’s Health was established at the NIH during President George H.W. Bush’s administration.
In April 2025, a few months after Trump took office, the Department of Health and Human Services decided to slash funding for the Women’s Health Initiative, a long-running, taxpayer-funded study of a broad range of women’s health issues that began in the 1990s. Officials restored the funding after a public outcry.
“These studies represent critical contributions to our better understanding of women’s health,” Emily G. Hilliard, a department spokeswoman, said at the time.
The new division will operate in coordination with the existing Office of Research on Women’s Health rather than replace it. Under the order, it must be established within an appropriate NIH institute or center within 90 days.
The White House said the move is intended to broaden the government’s focus beyond research and prioritize translating scientific discoveries into clinical care for women and girls.
Read More: Nearly 4,000 Measles Cases In US: CDC Director Says MMR Vaccine Is ‘Absolutely Safe’
Melania highlighted her “First Lady’s Five Pillars of Women’s Health Innovation,” which outline the initiative’s proposed approach:
The Women’s Health Task Force will work in collaboration with the private sector to advance new technologies and solutions for women’s health.
It aims to develop high-quality, scientifically supported medical information and care while advancing new treatments, therapies and cures for women.
It will be led by White House Chief of Staff Susie Wiles, who recently completed treatment for breast cancer, and Health and Human Services Secretary Robert F. Kennedy Jr.
While Trump said the panel will coordinate with various federal agencies and programs, the executive order does not specify funding targets.
According to the Department of Health and Human Services, the division will study conditions that uniquely or disproportionately affect women, including:
American singer and actress Selena Gomez has said that vaping nicotine has changed her voice, expressing concern that the effects may be irreversible.
"I'm not gonna be able to change my voice," the 34-year-old singer said in a candid Instagram post on Sunday. "I vaped nicotine a lot."
Describing how difficult it is to quit nicotine, Gomez added that "it's just not worth it".
"It is so stupid and..it changed my voice. So, if you guys don't like listening to my voice, that's totally understandable. I don't mind. Just don't listen to it. Just don't listen," she said.
Gomez also expressed hope that she would be able to quit vaping for good.
"It's really hard, but I know if you are going through something you can get through it too. It sucks," she added.
Vaping is often perceived as a cleaner alternative to smoking because e-cigarettes do not burn tobacco. However, the aerosol produced by these devices is not harmless water vapor and can contain substances that may affect respiratory and cardiovascular health.
E-cigarette aerosol may contain:
These substances may also affect the throat and vocal cords, potentially contributing to irritation, dryness and changes in voice quality.
Also read: 5.4 Million Over-16s Now Vape in Britain: Why E-Cigarettes May Not Be Safer
Research suggests that e-cigarette use may affect the vocal folds, the structures in the voice box that vibrate to produce sound.
A 2025 study published in the Journal of Voice examined the potential effects of e-cigarette use on vocal health.
“E-cigarette use can cause inflammation of the epithelium and mucosa of the vocal folds, and their components can cause dryness, compromising vocal homeostasis, increasing the risk of coughing and breathing difficulties, deteriorating the vocal folds, and worsening voice quality,” said the researchers from Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
By irritating and drying the vocal folds, e-cigarette aerosol may contribute to hoarseness, coughing and vocal strain. However, more research is needed to establish the long-term effects of vaping on the voice, including whether it can cause permanent voice changes.
Gomez, who has lupus, a chronic autoimmune disease, has previously suggested that she experiences throat swelling that may affect her voice.
During an Instagram Q&A in December, she said: "Sometimes things happen. I get weird. My throat kind of swells inside sometimes. That's all."
Lupus can affect different parts of the body and, in some cases, cause inflammation involving the larynx, or voice box. This may contribute to hoarseness, a raspy or breathy voice, vocal fatigue or changes in pitch.
It is not possible to determine whether Gomez's reported voice changes are related to vaping, lupus or another cause based on her public comments alone.
Persistent hoarseness, a raspy voice or difficulty speaking should not be ignored, particularly if symptoms do not improve. A clinician may examine the vocal cords to identify the cause.
People experiencing breathing difficulty or significant throat swelling should seek urgent medical attention.
Quitting vaping reduces further exposure to potentially irritating substances. Behavioral support and appropriate smoking-cessation treatments can help people manage nicotine dependence and withdrawal symptoms.
© $2026 Times Horizon Private Limited